ASXC - Asensus Surgical EPS beats by $0.01 misses on revenue

Asensus Surgical (NYSE:ASXC): Q2 Non-GAAP EPS of -$0.05 beats by $0.01; GAAP EPS of -$0.06 in-line. Revenue of $1.1M (+66.7% Y/Y) misses by $0.53M. The Company had cash and cash equivalents and restricted cash of approximately $158.1M as of June 30, 2021. Upcoming 2021 Milestones: For the full year 2021, the Company continues to expect to install 10 - 12 new Senhance Surgical Systems. During the second half of 2021, the Company expects to publish multiple clinical papers in peer reviewed journals highlighting health economic evidence comparing Senhance, robotics and laparoscopy in General Surgery and Gynecology across multiple procedures, specialties and hospitals. Press Release

For further details see:

Asensus Surgical EPS beats by $0.01, misses on revenue